KROS
Companies
NASDAQ
Keros Therapeutics Inc.
Health Care
$13.55
-$2.34 (-14.78%)
Price Chart
Overview
About KROS
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Market Cap
$1.8B
Volume
11.1M
Avg. Volume
16.4M
P/E Ratio
-2.480702
Dividend Yield
0.00%
Employees
120.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.52
High Correlation
Volatility
High (0.99)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, KROS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$1.8B
Volume11.1M
P/E Ratio-2.48
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 7, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025